CD5+ DLBCL patients had a significantly poorer EFS (median EFS: 10 months vs 65 months, P < 0.001) and OS (median OS: 18 vs 71 months, P < 0.001) than CD5− DLBCL patients (Figure 2A,D). The gene discussed is CD5; the disease is diffuse large B-cell lymphoma.